Linda Ibatá has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical practice guideline for psoriasis management in Latin America

    by Fernando Valenzuela, Juan Raúl Castro Ayarza, Débora Kaplan, Angela María Londoño-García, Karla del Rocío Macías García, Gabriel Magariños, Enrique Salvador Rivas Záldivar, Manuel Franco, Sara Cano, Carolina Cortés, et al.

  • Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )

    by Ángela María Londoño‐García, Juan Raúl Castro‐Ayarza, Manuel Darío Franco Franco, Paola Jimena Cárdenas Rojas, Carolina Ivette Cortés Correa, Natalia Montoya Moreno, Liliana María Tamayo Quijano, Edison Morales, Esperanza María Meléndez Ramírez, Ángela Seidel Arango, et al.

    Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. image

  • Open Access

    Expert Consensus on Diagnosis and Management of Secondary Sarcopenia in Adults in Colombia: A Modified Delphi Study

    by Claudia Contreras, Diana Paola Córdoba‐Rodríguez, Robinson Cuadros, José Ricardo Jauregui, Ángel Labán Castro Castro, Diana Trejos‐Gallego, Fernando Pereira, Susan Martínez, Linda Ibatá, Julieth Carolina Castillo

    Background: Secondary sarcopenia driven by chronic disease, acute illness, immobilization, malnutrition or treatment‐related factors contributes to functional decline, falls, disability, readmission and mortality. In Colombia, uneven access to body composition assessment, nutrition services and rehabilitation limits timely recognition and management. Methods: We conducted a modified Delphi expert consensus to develop Colombia‐focused recommendations for adults with suspected or confirmed secondary sarcopenia. Seven invited experts from geriatrics, intensive care medicine, clinical nutrition, physiotherapy, rehabilitation and surgery accepted participation and completed the consensus process. A structured evidence review from 2015 to 2025 informed 90 candidate statements across screening, diagnosis, nutrition, therapeutic exercise and follow‐up. Statements were rated using a 5‐point Likert scale. For each statement, a weighted consensus score was calculated as the sum of Likert scores divided by the maximum possible score and multiplied by 100. A weighted score of 70% or higher was prespecified as the approval threshold. Results: The 90 candidate statements were reduced to 50 final recommendations, representing a net reduction of 40 statements. The recommendations were organized into six thematic tables and address screening triggers, stepwise diagnostic confirmation, early interdisciplinary management, individualized nutrition strategies, structured multicomponent exercise and longitudinal reassessment using consistent baseline measures. Conclusions: This evidence‐informed expert consensus provides practical recommendations for screening, diagnosis, treatment and follow‐up of secondary sarcopenia in adults in Colombia. The document is intended as expert consensus guidance rather than a formal clinical practice guideline. Selected elements may be relevant to settings with similar access constraints, but external validation is required.

  • Open Access

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

    by Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco, Linda Ibatá, Susan Martínez, Álvaro Ruiz-Granados, Teresa Alonso-Gordoa

    PARP inhibitors (PARPi), alone or in combination with androgen receptor signaling inhibitors (ARSi), have shown clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), particularly in tumors with homologous recombination repair (HRR) gene alterations. Recent data from the TALAPRO-2 trial complete the current evidence on PARPi–ARSi combination strategies in this setting. Background/Objectives: To evaluate the efficacy and safety of PARPi-based therapies—monotherapy and combination with ARSi—in patients with mCRPC, focusing on molecular subgroups defined by DNA repair alterations. Methods: We conducted a systematic review and meta-analysis of phase III randomized controlled trials (RCTs) assessing PARPi as monotherapy or in combination with ARSi. Searches were performed in PubMed, EMBASE, the Cochrane Library, and oncology conference proceedings up to February 2025. Outcomes included radiographic progression-free survival (rPFS), overall survival (OS), second progression-free survival (PFS2), and grade ≥3 adverse events (AEs). Data were pooled using a random-effects model, with subgroup analyses by DNA repair status. Results: Five RCTs (n = 2921) were I confirmincluded: three on combination therapy (n = 2271) and two on monotherapy (n = 650). Combination therapy improved rPFS in the ITT (HR = 0.64; 95% CI: 0.56–0.74), HRRm (HR = 0.55; 95% CI: 0.44–0.68), and BRCAm (HR = 0.33; 95% CI: 0.18–0.58) subgroups. OS was also improved in the ITT (HR = 0.80; 95% CI: 0.70–0.92), HRRm (HR = 0.68; 95% CI: 0.55–0.83), and BRCAm (HR = 0.54; 95% CI: 0.34–0.85) groups. No benefit was observed in non-HRRm patients. PFS2 favored combination therapy (HR = 0.77; 95% CI: 0.64–0.91). Grade ≥3 AEs were more frequent (RR = 1.44; 95% CI: 1.20–1.73). Monotherapy improved rPFS in ITT (HR = 0.46; 95% CI: 0.20–0.81) and BRCAm (HR = 0.33; 95% CI: 0.15–0.75); OS benefit was seen only in BRCAm (HR = 0.73; 95% CI: 0.57–0.95). Conclusions: PARPi therapies improve outcomes mainly in HRR- and BRCA-mutated mCRPC. Molecular selection is key to optimizing benefit and minimizing toxicity. Further research on the activity of PARPi combinations in non-HRR mutated mCRPC is needed to better understand the underlying mechanisms of efficacy.


  • Open Access

    Consenso latino‐americano sobre redução gradual da terapia biológica na psoríase

    by Angela María Londoño García, Juan Raúl Castro‐Ayarza, Manuel Darío Franco Franco, Cesar Fernando González Ardila, Gabriel Magariños, Enrique Salvador Rivas Zaldívar, Susan Martínez, Linda Ibatá, Julieth Carolina Castillo, Paola Jimena Cárdenas Rojas, et al.

  • Open Access

    Latin American consensus on tapering of biological therapy in psoriasis

    by Angela María Londoño-García, Juan Raúl Castro-Ayarza, Manuel Darío Franco Franco, Cesar Fernando González Ardila, Gabriel Magariños, Enrique Salvador Rivas Zaldívar, Susan Martínez, Linda Ibatá, Julieth Carolina Castillo, Paola Jimena Cárdenas Rojas, et al.


  • Open Access

    Consenso latino‐americano sobre classificação da gravidade da psoríase

    by Angela María Londoño-García, Juan Raúl Castro‐Ayarza, Manuel Darío Franco, Cesar Fernando González Ardila, Gabriel Magariños, Enrique Salvador Rivas Zaldívar, Susan Martínez, Linda Ibatá, Julieth Carolina Castillo, Paola Jimena Cárdenas Rojas, et al.

  • Open Access

    Latin American consensus on psoriasis severity classification

    by Angela María Londoño-García, Juan Raúl Castro-Ayarza, Manuel Darío Franco Franco, Cesar Fernando González Ardila, Gabriel Magariños, Enrique Salvador Rivas Zaldívar, Susan Martínez, Linda Ibatá, Julieth Carolina Castillo, Paola Jimena Cárdenas Rojas, et al.


  • Open Access

    Diagnóstico y tratamiento de la dermatitis atópica en Colombia. Actualización de la guía de práctica clínica

    by Claudia Marcela Arenas-Soto, Gloria Sanclemente-Mesa, Juan José Yepes-Nuñez, Daniela Chaparro-Reyes, Jorge Sánchez, Liliana María Tamayo-Quijano, Martha Cecilia Valbuena-Mesa, Mauricio Torres-Pradilla, Natalia Velásquez-Gómez, Mariela Tavera-Zafra, et al.

    Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel altamente prevalente que afecta de manera negativa la calidad de vida de los pacientes y puede asociarse con comorbilidades sistémicas y afectación psicosocial. Se requiere la actualización de las guías de diagnóstico y tratamiento adecuado de la población y del contexto sanitario local. Objetivo: Esta actualización de la guía de práctica clínica (GPC), de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma), proporciona recomendaciones basadas en la evidencia para la evaluación y el manejo de la DA en Colombia, con un enfoque específico en tratamientos sistémicos, tópicos y terapias coadyuvantes, así como la gravedad y la gestión del riesgo. Estas recomendaciones están dirigidas a profesionales de la salud, tomadores de decisiones y pacientes. Métodos: Para desarrollar esta guía, se conformó un panel multidisciplinario de expertos y se llevó a cabo un proceso riguroso de revisión sistemática de la literatura para responder preguntas clínicas específicas. La certeza en la evidencia y la fuerza de las recomendaciones se evaluaron utilizando el enfoque GRADE (Grading of Recommendations Assessment, Development and Evaluation, por sus siglas en inglés). Resultados: El panel de expertos alcanzó consenso en once recomendaciones y nueve puntos de buena práctica para la atención de personas con DA. La revisión de la evidencia destaca la eficacia de crisaborol tópico, dupilumab, abrocitinib y upadacitinib en el manejo de la DA, con recomendaciones específicas para su uso en diferentes poblaciones. Se incluyen además recomendaciones para la descolonización de reservorios, la inmunoterapia con alérgenos y la restricción alimentaria, así como para la gestión del riesgo en el uso de terapias biológicas e inhibidores de las janocinasas (JAK, por sus siglas en inglés). Conclusiones: Esta guía proporciona recomendaciones actualizadas y basadas en la evidencia para el manejo integral de la DA en Colombia, considerando las necesidades específicas de adultos y niños. Se alienta a los profesionales de la salud a utilizar estas recomendaciones para optimizar la atención del paciente y mejorar los resultados clínicos.


  • Open Access

    Urgent-start peritoneal dialysis for patients with end-stage renal disease. A health technology assessment

    by Juan G. Ariza-Lozano, Linda M. Ibatá-Bernal, Susan Martínez, Isabel C. Saravia-Bermeo

    Objective: To analyze the available evidence on the relevant clinical and economic aspects of urgent-start peritoneal dialysis (US-PD) compared to urgent-sta...